Status:
COMPLETED
ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma
Lead Sponsor:
Institut Cancerologie de l'Ouest
Conditions:
Prostate Adenocarcinoma
Eligibility:
MALE
18+ years
Phase:
PHASE1
Brief Summary
This study will determine the delayed neurotoxicity (12 months) of a hypofractionated high dose irradiation (3 Gy x 9) associated with zoledronic acid. The administration of zoledronic acid repeat do...
Eligibility Criteria
Inclusion
- Adenocarcinoma of the prostate metastatic Age\> 18 years3.
- Life expectancy\> 12 months;
- Performance Index status \<3 PSA ≥ 4 ng / ml Zoledronic acid treatment in progress as recommended by the Authority for the Marketing Creatinine clearance above 30 ml / min Lack of maintenance causing disabling pain not lying down long (30 minutes) No history of radiotherapy to the region to be irradiated Absence of neurological signs compression Distance between the metastasis and spinal cord ≥ 5 mm Absence of metastases unstable metastatic epidural spinal cord compression or may require surgery before radiotherapy
Exclusion
- Concomitant treatment with a drug testing, participation in another clinical trial within \<30 days
- Presence of central system nervous desease (symptoms or progressive), Patient with a severe neurological disease, current manifestations of peripheral neuropathy\> grade 2 NCI-CTC V4 Existence of another severe pulmonary disease, liver or kidney, digestive likely to be exacerbated by treatment,
- Untreated with zoledronic acid
- Treatment with a bisphosphonate other than Zoledronic acid
- Clinically significant hypersensitivity to zoledronic acid, other bisphosphonates or to any excipients in the formulation of Zometa.
- Creatinine clearance below 30 ml / min
- History of another primary cancer (except basal cell skin cancer)
- Or demented patient with altered mental status who can not obtain informed consent. / Persons deprived of liberty or under guardianship
- Pain not resulting in maintaining the prolonged supine position (30 minutes)
- PSA below 4 ng / ml
- History of radiotherapy in localized tumor site
- Distance between the metastasis and spinal cord \<5 mm
- Monitoring impossible because of psychological, sociological or because of geographical distance.
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01219790
Start Date
October 1 2010
End Date
November 1 2015
Last Update
April 19 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Paul Papin
Angers, France, 49000
2
Centre Léon Bérard
Lyon, France, 69000
3
Centre René Gauducheau
Saint-Herblain, France, 44805